Molecular Mechanism of APOL1 Associated Kidney Disease

APOL1相关肾脏疾病的分子机制

基本信息

  • 批准号:
    8695481
  • 负责人:
  • 金额:
    $ 43.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-03 至 2018-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): More than 500,000 Americans suffer from end-stage renal disease (ESRD). African Americans develop ESRD at rates 4-5 fold higher than European Americans. Recently we showed that coding sequence variants in the ApolipoproteinL1 (ApoL1) gene, present only in individuals with recent African ancestry, explain a very large proportion of this health disparity. This has now been confirmed by multiple additional studies. ApoL1 variants have a major impact on different types of kidney disease including hypertension-associated ESRD, focal segmental glomerulosclerosis, and HIV-associated nephropathy. Individuals with two variant ApoL1 alleles have a 7-30 fold increased risk for kidney disease. 3.5 million African Americans likely have the high risk ApoL1 genotype. African Americans without two variant alleles have minimal excess risk. At present, little is known about the biology of ApoL1 or its rol in the kidney. ApoL1 has a defined role in resistance to trypanosomes, and the G1 and G2 variants appear to have become common in Africa because they confer protection against the forms of trypanosomes that cause African Sleeping Sickness. Here, our goal is to elucidate the function of ApoL1 and its role in causing human kidney disease in order to understand the biological mechanisms underlying this large disparity in kidney disease risk. ApoL1 is a Bcl2 family member with a BH3-only domain, suggesting a possible role in apoptosis. Our initial experiments in oocytes lead us to believe that this pathway may be an important mechanism of glomerular injury in ApoL1-associated disease. We propose to: 1. Define the cell biology and cell physiology of ApoL1: We will define the basic cellular biology of ApoL1 including biosynthesis, trafficking, ion channel properties, endocytosis, and effects on organellar structure and function. We will compare wild type and renal risk variant ApoL1 biology to understand the mechanisms that lead to kidney disease. 2. Examine specific effects of ApoL1 on apoptosis in podocytes: We hypothesize that ApoL1 risk variants promote podocyte apoptosis via a BH3 domain in the N- terminus and that the renal risk variants enhance ApoL1's pro-apoptotic effects. We will test this hypothesis both in cultured podocytes of different ApoL1 genotypes and by transfecting podocytes with ApoL1 constructs designed to probe the underlying apoptotic mechanisms. 3. Use a zebrafish model to study ApoL1- mediated renal injury in vivo: We will use zebrafish to understand how ApoL1 variants promote glomerular injury. We have demonstrated that the G1 risk variant increases embryonic lethality and causes glomerular pathology, and that wild type ApoL1 can reverse the pathologic phenotype caused by G1. We will examine the effects of heterologous ApoL1 expression in a whole organism using ubiquitous and tissue-specific promoters. We will define the risk variant domains that cause disease and the wild type domains that prevent G1-mediated injury. We will also define the specific interactions between the wild-type, G1, and G2 forms of ApoL1 in vivo. Lastly, we will examine the role of ApoL1 variants in promoting or preventing apoptosis of glomerular cells.
描述(由申请人提供):超过50万美国人患有终末期肾病(ESRD)。非裔美国人患ESRD的比率是欧裔美国人的4-5倍。最近,我们发现载脂蛋白l1 (ApoL1)基因的编码序列变异,仅存在于最近非洲血统的个体中,解释了这种健康差异的很大一部分。这一点现已得到多项额外研究的证实。ApoL1变异对不同类型的肾脏疾病有重要影响,包括高血压相关ESRD、局灶节段性肾小球硬化和hiv相关肾病。携带两个ApoL1变异等位基因的人患肾脏疾病的风险增加7-30倍。350万非洲裔美国人可能有高风险的ApoL1基因型。没有两个变异等位基因的非裔美国人的额外风险最小。目前,对ApoL1的生物学及其在肾脏中的作用知之甚少。ApoL1在对锥虫的抗性中具有明确的作用,并且G1和G2变体似乎在非洲已经变得普遍,因为它们赋予对引起非洲昏睡病的锥虫形式的保护。在这里,我们的目标是阐明ApoL1的功能及其在引起人类肾脏疾病中的作用,以了解肾脏疾病风险差异背后的生物学机制。ApoL1是Bcl2家族成员,具有BH3-only结构域,提示可能在细胞凋亡中起作用。我们在卵母细胞中的初步实验使我们相信这一途径可能是apol1相关疾病肾小球损伤的重要机制。我们建议:1。定义ApoL1的细胞生物学和细胞生理学:我们将定义ApoL1的基本细胞生物学,包括生物合成、运输、离子通道特性、内吞作用和对细胞器结构的影响

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SETH Leo ALPER其他文献

SETH Leo ALPER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SETH Leo ALPER', 18)}}的其他基金

Molecular Mechanism of APOL1 Associated Kidney Disease
APOL1相关肾脏疾病的分子机制
  • 批准号:
    8486603
  • 财政年份:
    2013
  • 资助金额:
    $ 43.5万
  • 项目类别:
Molecular Mechanism of APOL1 Associated Kidney Disease
APOL1相关肾脏疾病的分子机制
  • 批准号:
    8791547
  • 财政年份:
    2013
  • 资助金额:
    $ 43.5万
  • 项目类别:
Molecular Mechanism of APOL1 Associated Kidney Disease
APOL1相关肾脏疾病的分子机制
  • 批准号:
    9011946
  • 财政年份:
    2013
  • 资助金额:
    $ 43.5万
  • 项目类别:
Molecular Mechanism of APOL1 Associated Kidney Disease
APOL1相关肾脏疾病的分子机制
  • 批准号:
    9212011
  • 财政年份:
    2013
  • 资助金额:
    $ 43.5万
  • 项目类别:
RBC Ion Transporters as Hemoglobinopathy Risk Modifiers
红细胞离子转运蛋白作为血红蛋白病风险调节剂
  • 批准号:
    7030496
  • 财政年份:
    2006
  • 资助金额:
    $ 43.5万
  • 项目类别:
RBC Ion Transporters as Hemoglobinopathy Risk Modifiers
红细胞离子转运蛋白作为血红蛋白病风险调节剂
  • 批准号:
    7629010
  • 财政年份:
    2006
  • 资助金额:
    $ 43.5万
  • 项目类别:
RBC Ion Transporters as Hemoglobinopathy Risk Modifiers
红细胞离子转运蛋白作为血红蛋白病风险调节剂
  • 批准号:
    7435221
  • 财政年份:
    2006
  • 资助金额:
    $ 43.5万
  • 项目类别:
RBC Ion Transporters as Hemoglobinopathy Risk Modifiers
红细胞离子转运蛋白作为血红蛋白病风险调节剂
  • 批准号:
    7459154
  • 财政年份:
    2006
  • 资助金额:
    $ 43.5万
  • 项目类别:
RBC Ion Transporters as Hemoglobinopathy Risk Modifiers
红细胞离子转运蛋白作为血红蛋白病风险调节剂
  • 批准号:
    7245127
  • 财政年份:
    2006
  • 资助金额:
    $ 43.5万
  • 项目类别:
RBC Ion Transporters as Hemoglobinopathy Risk Modifiers
红细胞离子转运蛋白作为血红蛋白病风险调节剂
  • 批准号:
    7665605
  • 财政年份:
    2006
  • 资助金额:
    $ 43.5万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 43.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 43.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了